本頁面由Tiger Trade Technology Pte. Ltd.提供服務

諾和諾德

41.77
+0.13500.32%
成交量:936.87萬
成交額:3.93億
市值:1,864.81億
市盈率:10.78
高:42.30
開:42.03
低:41.70
收:41.63
52周最高:64.16
52周最低:35.12
股本:44.65億
流通股本:31.88億
量比:1.88
換手率:0.29%
股息:1.77
股息率:4.24%
每股收益(TTM):3.87
每股收益(LYR):3.62
淨資產收益率:58.38%
總資產收益率:19.05%
市淨率:5.82
市盈率(LYR):11.54

資料載入中...

2026/06/22

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2026/06/22

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2026/06/22

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/04/10

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/02/04

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/06/27

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/06/27

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/05/30

關聯方擬減持公告

Form 144 | Innate Pharma SA 10% 股東 Novo Nordisk A/S 擬減持921897股,總價約197萬美元
2025/02/05

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/21

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/06/21

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/01/31

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/11/24

SEC問詢函

Form CORRESP - Correspondence
2023/11/09

SEC問詢函

Form CORRESP - Correspondence
2023/10/20

SEC問詢函

Form CORRESP - Correspondence
2023/09/29

SEC問詢函

Form CORRESP - Correspondence
2023/09/13

SEC問詢函

Form CORRESP - Correspondence
2023/06/28

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/06/28

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/02/01

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]